Tamara Pringsheim1, Lauren Hirsch2, David Gardner3, Daniel A Gorman4. 1. Assistant Professor, Department of Clinical Neurosciences, Psychiatry, Community Health Sciences, and Pediatrics, University of Calgary, Calgary, Alberta; Neurologist, Director, Calgary Tourette and Paediatric Movement Disorders Clinic, Calgary, Alberta. 2. Student, Community Health Sciences, University of Calgary, Calgary, Alberta. 3. Professor, Department of Psychiatry and Pharmacy, Dalhousie University, Halifax, Nova Scotia. 4. Assistant Professor, Department of Psychiatry, University of Toronto, Toronto, Ontario.
Abstract
OBJECTIVE: Children with attention-deficit hyperactivity disorder (ADHD) may have oppositional behaviour, conduct problems, and aggression. These symptoms vary in severity, and may be related to a comorbid diagnosis of oppositional defiant disorder (ODD) or conduct disorder (CD). Critical evaluation of the efficacy of ADHD medications may guide the clinician regarding the usefulness of medications for these symptoms. METHOD: We performed a systematic review and meta-analysis of psychostimulants, alpha-2 agonists, and atomoxetine for oppositional behaviour, conduct problems, and aggression in youth with ADHD, ODD, and CD. The quality of evidence for medications was rated using the Grading of Recommendations Assessment, Development and Evaluation approach. RESULTS: Two systematic reviews and 20 randomized controlled trials were included. There is high-quality evidence that psychostimulants have a moderate-to-large effect on oppositional behaviour, conduct problems, and aggression in youth with ADHD, with and without ODD or CD. There is very-low-quality evidence that clonidine has a small effect on oppositional behaviour and conduct problems in youth with ADHD, with and without ODD or CD. There is moderate-quality evidence that guanfacine has a small-to-moderate effect on oppositional behaviour in youth with ADHD, with and without ODD. There is high-quality evidence that atomoxetine has a small effect on oppositional behaviour in youth with ADHD, with and without ODD or CD. CONCLUSIONS: Evidence indicates that psychostimulants, alpha-2 agonists, and atomoxetine can be beneficial for disruptive and aggressive behaviours in addition to core ADHD symptoms; however, psychostimulants generally provide the most benefit.
OBJECTIVE:Children with attention-deficit hyperactivity disorder (ADHD) may have oppositional behaviour, conduct problems, and aggression. These symptoms vary in severity, and may be related to a comorbid diagnosis of oppositional defiant disorder (ODD) or conduct disorder (CD). Critical evaluation of the efficacy of ADHD medications may guide the clinician regarding the usefulness of medications for these symptoms. METHOD: We performed a systematic review and meta-analysis of psychostimulants, alpha-2 agonists, and atomoxetine for oppositional behaviour, conduct problems, and aggression in youth with ADHD, ODD, and CD. The quality of evidence for medications was rated using the Grading of Recommendations Assessment, Development and Evaluation approach. RESULTS: Two systematic reviews and 20 randomized controlled trials were included. There is high-quality evidence that psychostimulants have a moderate-to-large effect on oppositional behaviour, conduct problems, and aggression in youth with ADHD, with and without ODD or CD. There is very-low-quality evidence that clonidine has a small effect on oppositional behaviour and conduct problems in youth with ADHD, with and without ODD or CD. There is moderate-quality evidence that guanfacine has a small-to-moderate effect on oppositional behaviour in youth with ADHD, with and without ODD. There is high-quality evidence that atomoxetine has a small effect on oppositional behaviour in youth with ADHD, with and without ODD or CD. CONCLUSIONS: Evidence indicates that psychostimulants, alpha-2 agonists, and atomoxetine can be beneficial for disruptive and aggressive behaviours in addition to core ADHD symptoms; however, psychostimulants generally provide the most benefit.
Authors: Daniel F Connor; Stephen J Glatt; Ivan D Lopez; Denise Jackson; Richard H Melloni Journal: J Am Acad Child Adolesc Psychiatry Date: 2002-03 Impact factor: 8.829
Authors: Scott H Kollins; Rakesh Jain; Matthew Brams; Scott Segal; Robert L Findling; Sharon B Wigal; Moise Khayrallah Journal: Pediatrics Date: 2011-05-09 Impact factor: 7.124
Authors: Timothy E Wilens; Keith McBurnett; Oscar Bukstein; James McGough; Laurence Greenhill; Marc Lerner; Mark A Stein; C Keith Conners; John Duby; Jeffrey Newcorn; Charles E Bailey; Christopher J Kratochvil; Daniel Coury; Charles Casat; Mary Joan C Denisco; Patricia Halstead; Leslie Bloom; Brenda A Zimmerman; Joan Gu; Kimberly M Cooper; Joseph M Lynch Journal: Arch Pediatr Adolesc Med Date: 2006-01
Authors: M L Wolraich; L L Greenhill; W Pelham; J Swanson; T Wilens; D Palumbo; M Atkins; K McBurnett; O Bukstein; G August Journal: Pediatrics Date: 2001-10 Impact factor: 7.124
Authors: Daniel F Connor; Robert L Findling; Scott H Kollins; Floyd Sallee; Frank A López; Andrew Lyne; Gerald Tremblay Journal: CNS Drugs Date: 2010-09 Impact factor: 5.749
Authors: Jason Kung; Francesco Chiappelli; Olivia O Cajulis; Raisa Avezova; George Kossan; Laura Chew; Carl A Maida Journal: Open Dent J Date: 2010-07-16
Authors: Mark L Wolraich; Joseph F Hagan; Carla Allan; Eugenia Chan; Dale Davison; Marian Earls; Steven W Evans; Susan K Flinn; Tanya Froehlich; Jennifer Frost; Joseph R Holbrook; Christoph Ulrich Lehmann; Herschel Robert Lessin; Kymika Okechukwu; Karen L Pierce; Jonathan D Winner; William Zurhellen Journal: Pediatrics Date: 2019-10 Impact factor: 7.124
Authors: Daniel A Gorman; David M Gardner; Andrea L Murphy; Mark Feldman; Stacey A Bélanger; Margaret M Steele; Khrista Boylan; Kate Cochrane-Brink; Roxanne Goldade; Paul R Soper; Judy Ustina; Tamara Pringsheim Journal: Can J Psychiatry Date: 2015-02 Impact factor: 4.356